📝 Bharat Parenterals Ltd — results explained
Quarter ended June 2026 (Q1 FY27)
Bharat Parenterals Ltd reported revenue of ₹56 crore for the quarter ended June 2026 (Q1 FY27), down 41.2% from ₹94 crore in the same quarter last year, and down 1.8% sequentially over the March 2026 quarter.
Net profit fell 63.4% year-on-year to ₹4 crore, from ₹10 crore. Earnings per share (EPS) came in at ₹5.31.
Operating profit stood at ₹7 crore — an operating margin (OPM) of 12.3%, compared with 16.2% in the year-ago quarter.
Full year and trailing twelve months
For the full year FY26, Bharat Parenterals Ltd posted revenue of ₹234 crore, a decline of 23.1% over FY25, with a net profit of ₹16 crore (down 39.4% year-on-year).
On a trailing-twelve-month (TTM) basis, revenue stands at ₹195 crore with a net profit of ₹10 crore.
Valuation snapshot
At the current price of ₹1,517.05, 541096 has a market capitalisation of ₹1,062 crore and a trailing P/E of about 109.6.
Within the Pharmaceuticals industry, it is the 9th-largest of the 82 companies we track by market value.
Shareholding pattern
As of Jun 2026, promoters held 67.20%, foreign institutional investors (FIIs) 0.11%, domestic institutional investors (DIIs) 1.38%, public shareholders 31.31% of Bharat Parenterals Ltd.